Mpox (monkeypox) vaccine Vaccine safety data Main navigation COVID-19 vaccines Influenza vaccines National Immunisation Program schedule vaccines Mpox (monkeypox) vaccine Intradermal JYNNEOS Mpox (monkeypox) vaccine Subcutaneous JYNNEOS mpox (monkeypox) vaccine Shingrix® Mpox vaccine safety surveillance conducted by AusVaxSafety was completed on 17 April 2023. Data on this page will no longer be updated. Safety data collected from more than 15,000 JYNNEOS mpox vaccine recipients identified no safety issues in either administration method, intradermal and subcutaneous. The Therapeutic Goods Administration (TGA) continues to monitor the safety of mpox vaccines in Australia. Mpox vaccine safety data Click on the tiles below to view subcutaneous and intradermal mpox vaccine safety data. Intradermal JYNNEOS mpox (monkeypox) vaccine View the latest intradermal JYNNEOS mpox vaccine safety data here Subcutaneous JYNNEOS mpox (monkeypox) vaccine View the latest subcutaneous JYNNEOS mpox vaccine safety data here Vaccine safety data Main navigation COVID-19 vaccines Influenza vaccines National Immunisation Program schedule vaccines Mpox (monkeypox) vaccine Intradermal JYNNEOS Mpox (monkeypox) vaccine Subcutaneous JYNNEOS mpox (monkeypox) vaccine Shingrix® News & events All news & events 08 March 2024 | News Vaccine safety in Australia AusVaxSafety summary report now available 20 February 2024 | News What to expect in the days after your XBB.1.5 COVID-19 vaccine 20 December 2023 | News Shingrix® vaccine safety data now available 28 November 2023 | News AusVaxSafety monitoring monovalent Omicron XBB.1.5 variant COVID-19 vaccine safety